BNGO Bionano Genomics, Inc.: institutional ownership and insider trading
35 funds reported holding $928K of Bionano Genomics, Inc. in their latest 13F filings; in Q2 2026 funds net sold $182K, with 8 new positions and 6 funds selling out; over the last 12 months insiders bought $9.72K and sold $0 on the open market; over its last four quarters it reported revenue of $30.2M and net income of −$32.2M.
BNGO revenue and earnings
- Quarter ended Jun 30, 2026: revenue $8.17M, net income −$7.42M, EPS -0.64
- Quarter ended Mar 31, 2026: revenue $6.69M, net income −$8.30M, EPS -0.76
- Quarter ended Dec 31, 2025: revenue $7.95M, net income −$7.93M, EPS -0.12
- Quarter ended Sep 30, 2025: revenue $7.37M, net income −$8.50M, EPS -1.59
Famous investors holding BNGO
- Renaissance Technologies (Renaissance Technologies): $57.7K, 0.0% of the portfolio
Largest institutional holders of BNGO
- GSA CAPITAL PARTNERS LLP — $170K
- CARRET ASSET MANAGEMENT, LLC — $141K
- VANGUARD GROUP INC — $126K
- GEODE CAPITAL MANAGEMENT, LLC — $102K
- VANGUARD CAPITAL MANAGEMENT LLC — $93.1K
- VANGUARD FIDUCIARY TRUST CO — $58.3K
- RENAISSANCE TECHNOLOGIES LLC — $57.7K
- JANE STREET GROUP, LLC — $40.4K
- PRUDENTIAL FINANCIAL INC (PFH, PRH, PRS, PRU) — $35.7K
- NORTHERN TRUST CORP (NTRS, NTRSO) — $27.8K
Recent BNGO insider trades
- Sep 4, 2026: Luderer Albert bought 4,000 shares ($4.84K)
- Aug 21, 2026: Luderer Albert bought 4,000 shares ($4.88K)
5%+ owners
- CVI Investments, Inc.: 9.9% (Schedule 13G/A, filed Aug 14, 2026)
- Orin Hirschman: 9.9% (Schedule 13G, filed Oct 19, 2026)
Who owns the most BNGO stock?
The largest institutional holders of Bionano Genomics, Inc. in the latest 13F filings are GSA CAPITAL PARTNERS LLP ($170K), CARRET ASSET MANAGEMENT, LLC ($141K), VANGUARD GROUP INC ($126K).
Are insiders buying or selling BNGO?
Over the last 12 months insiders bought $9.72K and sold $0 of Bionano Genomics, Inc. stock on the open market (SEC Form 4).
Which famous investors own BNGO?
Renaissance Technologies.
What was BNGO's revenue last quarter?
Bionano Genomics, Inc. reported revenue of $8.17M for the quarter ended June 30, 2026, with net income of −$7.42M.